Ezetimibe Side Effects: What the Clinical Evidence Shows

How Ezetimibe Works and Why Side Effects Differ From Statins

Ezetimibe targets the NPC1L1 protein on the brush border of the small intestine, blocking dietary and biliary cholesterol absorption. This mechanism is entirely distinct from statins, which inhibit HMG-CoA reductase in the liver to reduce cholesterol synthesis. Because ezetimibe does not interfere with the mevalonate pathway (the same pathway statins block that also produces coenzyme Q10 and other molecules), it avoids several side effects commonly attributed to statin therapy. In clinical practice, this pharmacological distinction translates into a different and generally milder side effect profile.

Overall Safety in Large Clinical Trials

The largest systematic review on ezetimibe safety, published in BMJ Medicine in 2022, pooled data from 48 randomized controlled trials covering 28,444 patients with follow-up periods ranging from 24 to 312 weeks. The meta-analysis found moderate to high certainty evidence that ezetimibe was not associated with increased cancer risk (relative risk 1.01, 95% CI 0.92 to 1.11), fractures (RR 0.90, 95% CI 0.74 to 1.10), neurocognitive events, or new-onset diabetes (RR 0.88, 95% CI 0.61 to 1.28). Discontinuation rates due to adverse events were similar between ezetimibe and comparator groups.

Four observational studies with a median follow-up of roughly 5 to 7.5 years confirmed these findings in real-world populations. The bottom line from this analysis: ezetimibe results in little to no difference in adverse events compared with placebo, usual care, or other lipid-lowering agents.

Muscle-Related Side Effects: Myalgia, CK Elevation, and Rhabdomyolysis

Muscle complaints are the most feared side effect of cholesterol drugs, but ezetimibe consistently shows a favorable profile here. A 2008 systematic review of 18 randomized trials (14,471 patients) found that adding ezetimibe to statin therapy did not increase myalgia risk (risk difference -0.033, 95% CI -0.06 to -0.01), creatine kinase elevations, rhabdomyolysis, or discontinuations due to muscle symptoms compared with statin alone.

A more recent 2024 meta-analysis of 32 studies (12,042 patients) went further, showing that patients on low-to-moderate intensity statins plus ezetimibe actually had significantly lower myalgia rates (RR 0.27, 95% CI 0.13 to 0.57) and fewer discontinuations (RR 0.61, 95% CI 0.51 to 0.74) than those on high-intensity statin monotherapy. In other words, adding ezetimibe to a lower statin dose may reduce muscle side effects compared to simply increasing the statin.

Individual case reports do exist. One published case described myopathy developing 16 days after adding ezetimibe to high-dose atorvastatin, with symptoms resolving 12 days after stopping ezetimibe. These cases are rare, and the large trial data suggest they represent outliers rather than a systematic risk signal.

Liver Effects: Transaminase Elevations and Rare Hepatotoxicity

Mild liver enzyme elevations (ALT or AST exceeding three times the upper limit of normal) occur in fewer than 1-2% of patients on ezetimibe, at rates similar to placebo or statin monotherapy. These elevations are typically asymptomatic and reversible. The 2008 Kashani review of 18 trials confirmed no significant increase in transaminase elevations with combination ezetimibe-statin therapy versus statin alone.

Severe liver injury from ezetimibe is extremely rare but has been documented. A 2006 case series described two patients who developed distinct patterns of hepatotoxicity: one with severe cholestatic hepatitis and another with acute autoimmune-like hepatitis. A 2007 report documented drug-induced liver injury associated with ezetimibe, noting that most cases were asymptomatic and reversible. These case reports are important to know about, but they number in the single digits across millions of prescriptions.

Combination Therapy With Statins: Does Adding Ezetimibe Increase Risk?

The RACING trial (3,780 patients, published in The Lancet in 2022) directly compared moderate-intensity rosuvastatin 10 mg plus ezetimibe 10 mg against high-intensity rosuvastatin 20 mg alone in patients with established cardiovascular disease. The combination group had a primary endpoint rate of 9.1% versus 9.9% for high-intensity statin monotherapy (non-inferior). Critically, intolerance-related drug discontinuation or dose reduction was significantly lower in the combination group: 4.8% versus 8.2% (p<0.0001).

The IMPROVE-IT trial provided even longer follow-up. Among 2,798 patients aged 75 and older followed for a median of 6 years, simvastatin plus ezetimibe reduced the primary cardiovascular endpoint by 8.7% (HR 0.80, 95% CI 0.70 to 0.90) compared with simvastatin alone, with no increase in liver events, muscle events, gallbladder disease, or cancer. A 2025 meta-analysis in Mayo Clinic Proceedings (108,373 patients across 14 studies) confirmed that combination therapy significantly reduced all-cause mortality (OR 0.81, 95% CI 0.67 to 0.97) and stroke (OR 0.83, 95% CI 0.75 to 0.91) with comparable adverse event rates.

Real-World Pharmacovigilance Data

A 2024 analysis of the FDA Adverse Event Reporting System (FAERS) examined 11,550 adverse drug event reports involving ezetimibe from 2004 to 2023. The study identified 211 preferred adverse event terms across 24 organ system classes. New disproportionate safety signals included unstable angina (n=120, reporting odds ratio 30.53), crush syndrome (n=19, ROR 298.83), and rhabdomyolysis.

FAERS data has important limitations. It captures voluntary reports and cannot establish causation. Many reported cases involve patients on multiple medications, making attribution difficult. The signal for unstable angina, for example, likely reflects the underlying cardiovascular disease in patients prescribed ezetimibe rather than a drug effect. Still, pharmacovigilance data serves as an early warning system, and clinicians should remain alert to unusual symptom patterns.

Who Should Be Cautious

Ezetimibe is contraindicated in combination with a statin during pregnancy or in patients with active liver disease. Patients with moderate to severe hepatic impairment may have increased ezetimibe exposure. Anyone who has experienced a hypersensitivity reaction to ezetimibe should avoid it. For patients on cyclosporine, monitoring is recommended because cyclosporine can increase ezetimibe blood levels.

Routine liver enzyme monitoring is reasonable when starting ezetimibe, particularly in combination with a statin, though the overall incidence of clinically significant liver injury is very low. If unexplained muscle pain, tenderness, or weakness develops, checking a creatine kinase level is appropriate. Most patients tolerate ezetimibe without incident.

The Bottom Line on Ezetimibe Safety

Across 48 randomized trials, large observational studies, and nearly two decades of pharmacovigilance data, ezetimibe has a consistently favorable safety profile. It does not increase cancer risk, fracture risk, diabetes risk, or neurocognitive events. Muscle side effects are not more common than placebo, and combining ezetimibe with a moderate-dose statin can actually reduce myalgia compared to high-intensity statin monotherapy. Severe hepatotoxicity exists in isolated case reports but is exceedingly rare.

For people who need additional LDL-C lowering beyond what a statin provides, or for those who cannot tolerate higher statin doses, ezetimibe offers meaningful cholesterol reduction with minimal additional risk. The evidence supports its role as a well-tolerated, effective component of lipid-lowering therapy.